Boosting the Innate Immune System

Even with current vaccines, anti-virals and antibiotics
significant unmet needs remain to better prevent and treat respiratory infections


Pulmotect technology has demonstrated activity
and completed Phase I clinical trials to address these unmet needs

IMMUNOCOMPROMISED PATIENTS

Forecast sales for the immuno-stimulants market are estimated to reach $17.6 billion

~ The Cancer Market Outlook:
Competitive landscape, pipeline analysis
and growth opportunities

EPIDEMIC

More than 2 billion people worldwide
could be impacted by a pandemic. 160 million Americans will need to be vaccinated.

~TIME

 CDC Declares 2015 Flu Epidemic

 

EMERGING PATHOGENS

Despite remarkable advances in medical research and treatments during the 20th century, infectious diseases remain among the leading causes of death worldwide.

~ National Institute of
Allergy and Infectious Disease

 

Our Products

Remarkably, despite a surface area nearly the size of a tennis court,
the lungs are typically capable of defending themselves against inhaled pathogens.  

Our Research

Inducible epithelial resistance protects mice against pneumonia
Blood. 2016 Aug 18. Volume 128(7): 982-92. doi: 10.1182/blood-2016-03-708511.

The Market

PULMOTECT’S NOVEL PROPRIETARY TECHNOLOGY provides access to an estimated $50-100 billion infectious disease market by addressing significant unmet needs in the prevention of infections